FDA Approves New Treatment for Kidney Condition
Adults with primary IgAN now have access to a new therapy shown to reduce proteinuria in clinical trials.
Updated on Oct. 27, 2026 in Allergies
Live Poll
Do you trust pharmaceutical companies to prioritize patient health over the pricing of new drug therapies?
The FDA has granted accelerated approval to the drug Ultomiris for reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). This treatment offers a new option for individuals managing this progressive kidney condition.
Why it matters
Reducing proteinuria is a clinical priority because approximately half of patients with elevated protein or reduced kidney function face a high risk of progressing to kidney failure within 10 years of diagnosis. This approval aims to help slow that progression by targeting underlying inflammation.
In a Phase 3 trial, Ultomiris demonstrated a 43.4% reduction in proteinuria versus placebo at 34 weeks among adults with primary IgAN. As this is an accelerated approval based on an interim analysis, long-term clinical benefits are still being verified in the ongoing I CAN trial.
The players
FDA
The federal agency responsible for evaluating the safety and efficacy of new medical therapies in the United States.
Alexion
A pharmaceutical company headquartered in Boston that specializes in developing treatments for rare diseases.
AstraZeneca
A global biopharmaceutical firm based in Cambridge that focuses on oncology, cardiovascular, and renal health.
The details
Ultomiris works by inhibiting the C5 protein within the terminal complement cascade. By blocking this specific part of the immune system, the therapy prevents the body from attacking healthy cells and causing inflammation in the kidneys. Patients receive the medication through an intravenous infusion, beginning with an initial loading dose followed by maintenance doses every eight weeks.
Timeline
Day 1: Patients receive an initial loading dose of the therapy.
Week 34: Trial participants showed a measured reduction in proteinuria.
21 October 2026: The FDA formally announced the drug approval.
23 October 2026: Trial results were presented at Kidney Week 2026.
Health Landscape
This development follows a pattern set by the I CAN Phase III trial, which provided the clinical framework for the drug's accelerated approval. It represents a shift in IgAN treatment by targeting the terminal complement pathway to manage kidney damage at the molecular level.
If you are living with primary IgAN, this therapy represents a new treatment pathway that may help reduce proteinuria and potentially slow disease progression. It is a topic worth discussing with your nephrologist to determine if this therapy is appropriate for your specific health profile.
The takeaway
Targeting the terminal complement pathway may help preserve kidney function in those with primary IgAN. Patients should discuss their current risk of progression and potential new treatment options with a kidney specialist during their next appointment.
Further reading
For more information on managing chronic kidney conditions, visit our Allergies section.
Source note: This article includes information reported by Drugs.
Live Poll
Do you trust pharmaceutical companies to prioritize patient health over the pricing of new drug therapies?
